{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:44:24Z","timestamp":1791229464456,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clinthera.2023.01.016","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T10:40:49Z","timestamp":1677235249000},"page":"278-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-9722","authenticated-orcid":false,"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Shteinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"Cohen-Cymberknoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.01.016_bib0001","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study","volume":"56","author":"Andersen","year":"1938","journal-title":"Am J Dis Children"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0002","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0003","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0004","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0005","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0006","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0007","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0008","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0010","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MCP.0000000000000819","article-title":"Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world\u2014opportunities and challenges","volume":"27","author":"Barry","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0011","unstructured":"Cystic Fibrosis Foundation. 2021 Annual Data Report. https:\/\/www.cff.org\/medical-professionals\/patient-registry (2022, accessed 12 December 2022)."},{"key":"10.1016\/j.clinthera.2023.01.016_bib0012","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcf.2017.08.009","article-title":"Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis","volume":"17","author":"Kazmerski","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2016.10.012","article-title":"Contraceptive choices and preferences in a cohort of women with cystic fibrosis","volume":"121","author":"Roe","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0014","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.contraception.2020.02.006","article-title":"Contraceptive use among women with cystic fibrosis: a pilot study linking reproductive health questions to the Cystic Fibrosis Foundation National Patient Registry","volume":"101","author":"Godfrey","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ppul.22967","article-title":"The cystic fibrosis gender gap: potential roles of estrogen","volume":"49","author":"Sweezey","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0016","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMoa1106126","article-title":"Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis","volume":"366","author":"Chotirmall","year":"2012","journal-title":"N Engl J Med"},{"issue":"S2","key":"10.1016\/j.clinthera.2023.01.016_bib0017","article-title":"Effect of sex hormones on markers of health in women with cystic fibrosis","volume":"54","author":"Jain","year":"2019","journal-title":"Pediatric Pulmonology"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0018","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpag.2020.07.014","article-title":"Hormonal contraception effects on pulmonary function in adolescents with cystic fibrosis","volume":"33","author":"Perrissin-Fabert","year":"2020","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0019","first-page":"1","article-title":"U.S. Medical Eligibility Criteria for Contraceptive Use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcf.2017.07.017","article-title":"Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis","volume":"17","author":"Kazmerski","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0021","first-page":"853","article-title":"Drug interactions between oral contraceptives and antibiotics","volume":"98","author":"Dickinson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajog.2017.07.003","article-title":"Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review","volume":"218","author":"Simmons","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0023","unstructured":"Lumacaftor\/ivacaftor (Orkambi), United States Prescribing Information."},{"key":"10.1016\/j.clinthera.2023.01.016_bib0024","unstructured":"Ivacaftor (Kalydeco), United States Prescribing Information."},{"key":"10.1016\/j.clinthera.2023.01.016_bib0025","unstructured":"Tezacaftor\/ivacaftor (Symdeko), United States Prescribing Information."},{"key":"10.1016\/j.clinthera.2023.01.016_bib0026","unstructured":"Elexacaftor\/tezacaftor\/ivacaftor (Trikafta), United States Prescribing Information."},{"key":"10.1016\/j.clinthera.2023.01.016_bib0027","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2018.10.009","article-title":"Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age","volume":"18","author":"Shteinberg","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0028","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0015-0282(16)39790-4","article-title":"Water and electrolytes in cervical mucus from patients with cystic fibrosis","volume":"24","author":"Kopito","year":"1973","journal-title":"Fertil Steril"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0029","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1001\/jama.1996.03540200024023","article-title":"Hypofertility with thick cervical mucus: another mild form of cystic fibrosis?","volume":"276","author":"Gervais","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0030","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/humrep\/13.8.2092","article-title":"Female patients with cystic fibrosis suffer from reproductive endocrinological disorders despite good clinical status","volume":"13","author":"Johannesson","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0031","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mce.2005.12.032","article-title":"Critical role of CFTR in uterine bicarbonate secretion and the fertilizing capacity of sperm","volume":"250","author":"Chan","year":"2006","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0032","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00001756-199701200-00031","article-title":"Cystic fibrosis mRNA expression in rat brain: cerebral cortex and medial preoptic area","volume":"8","author":"Johannesson","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0033","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1210\/en.2007-1581","article-title":"Infertility in females with cystic fibrosis is multifactorial: evidence from mouse models","volume":"149","author":"Hodges","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0034","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jcf.2014.09.008","article-title":"Cystic fibrosis (cf) and ovarian reserve: a cross-sectional study examining serum anti-mullerian hormone (amh) in young women","volume":"14","author":"Schram","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.01.016_bib0036","first-page":"25","article-title":"Potential impact on fertility of new systemic therapies for cystic fibrosis","volume":"16","author":"Jones","year":"2015","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0037","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.chest.2021.07.024","article-title":"Fertility and pregnancy in cystic fibrosis","volume":"160","author":"Shteinberg","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2014.07.018","article-title":"Medical and obstetric complications among pregnant women with cystic fibrosis","volume":"212","author":"Patel","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0039","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/14767058.2016.1161747","article-title":"Maternal co-morbidities and neonatal outcomes associated with cystic fibrosis","volume":"30","author":"Jelin","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0040","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jcf.2017.09.006","article-title":"Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0041","first-page":"260","article-title":"Acute clinical outcomes following participation in short-term CFTR modulator trials in adults with cystic fibrosis: a retrospective chart review","volume":"53","author":"Carpino","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0042","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators\u2014an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0043","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0044","doi-asserted-by":"crossref","first-page":"S393","DOI":"10.1016\/j.ajog.2021.11.658","article-title":"Trikafta in pregnancy: a clinical case series","volume":"226","author":"Burn","year":"2022","journal-title":"Am J Obstetrics Gynecol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and ivacaftor","volume":"21","author":"Collins","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0046","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","article-title":"Measured fetal and neonatal exposure to lumacaftor and ivacaftor during pregnancy and while breastfeeding","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0047","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0048","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0049","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/1359105320916539","article-title":"How do cystic fibrosis patients experience parenthood? A systematic review","volume":"26","author":"Jacob","year":"2021","journal-title":"J Health Psychol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0051","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/00365548.2012.708942","article-title":"Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients","volume":"45","author":"Hoek","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0052","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1080\/13548506.2016.1233345","article-title":"\u2018I've got to prioritise\u2019: being a parent with cystic fibrosis","volume":"22","author":"Barker","year":"2017","journal-title":"Psychol Health Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0053","first-page":"438","article-title":"Pregnancy and delivery in a patient with cystic fibrosis of the pancreas: report of a case","volume":"16","author":"Siegel","year":"1960","journal-title":"Obstetrics Gynecol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0054","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1378\/chest.124.4.1460","article-title":"The effect of pregnancy on survival in women with cystic fibrosis","volume":"124","author":"Goss","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201211-108OC","article-title":"Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis","volume":"10","author":"Schechter","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0056","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jcf.2022.02.006","article-title":"Parenthood impacts short-term health outcomes in people with cystic fibrosis","volume":"21","author":"Kazmerski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0057","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199502233320803","article-title":"The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group","volume":"332","author":"Neglia","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0058","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jnci\/djs481","article-title":"Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States","volume":"105","author":"Maisonneuve","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0059","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/ijc.24679","article-title":"Cancer risk among patients with cystic fibrosis and their first-degree relatives","volume":"125","author":"Johannesson","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2016.07.011","article-title":"Cancer risk among lung transplant recipients with cystic fibrosis","volume":"16","author":"Fink","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0061","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2017.12.012","article-title":"Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations","volume":"154","author":"Hadjiliadis","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0062","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13256-021-03234-1","article-title":"Malignancies in patients with cystic fibrosis: a case series","volume":"16","author":"Appelt","year":"2022","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0063","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0064","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/M15-2886","article-title":"Screening for breast cancer: US Preventive Services Task Force Recommendation Statement","volume":"164","author":"Siu","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0066","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"issue":"Pt 7","key":"10.1016\/j.clinthera.2023.01.016_bib0067","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1099\/0022-1317-66-7-1515","article-title":"The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours","volume":"66","author":"Durst","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0068","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-132-10-200005160-00009","article-title":"Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review","volume":"132","author":"Nanda","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0069","first-page":"321","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society","volume":"70","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0070","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0071","unstructured":"US Preventive Services Task Force. Ovarian Cancer: Screening. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/document\/RecommendationStatementFinal\/ovarian-cancer-screening (accessed 8 July 2022)."},{"key":"10.1016\/j.clinthera.2023.01.016_bib0072","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0073","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jpag.2020.12.004","article-title":"Human papilloma virus vaccination among female patients attending French pediatric cystic fibrosis centers","volume":"34","author":"Rousset-Jablonski","year":"2021","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0074","first-page":"7","article-title":"American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archpedi.153.1.27","article-title":"Preventive services received by adolescents with cystic fibrosis and sickle cell disease","volume":"153","author":"Britto","year":"1999","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0076","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ppul.23321","article-title":"Cystic fibrosis program directors\u2019 attitudes toward sexual and reproductive health in young women with CF","volume":"51","author":"Kazmerski","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0077","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/humrep\/dev217","article-title":"Contraceptive practices and cervical screening in women with cystic fibrosis","volume":"30","author":"Rousset Jablonski","year":"2015","journal-title":"Hum Reprod"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0078","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejogrb.2017.12.005","article-title":"High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis","volume":"221","author":"Rousset-Jablonski","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.clinthera.2023.01.016_bib0079","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1569-1993(22)00724-X","article-title":"Cystic fibrosis in the United States by 2040: a population landscape analysis","volume":"21","author":"Cromwell","year":"2022","journal-title":"J Cystic Fibrosis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182300036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182300036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:59:20Z","timestamp":1758963560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182300036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S014929182300036X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}